Big pharmaceutical companies in the US are rejoicing over a new Food and Drug Administration ruling that gives them an extension of 3 years on their drug patents. Consumer groups are not exactly delighted at the change because it could cost consumers billions of dollars, since companies that make cheaper "generic" alternatives to brand-name drugs on which the patents have expired would be left out in the cold. These companies have called on the Congress to amend the law.